ビタブリッドジャパン
TSE Growth ・ Ticker 542A ・ Listed
Offer price
1,370 yen
First traded price
1,301 yen
Selling 100 shares at the first traded price would have produced a loss of 6,900 yen, before fees and tax. 100 shares is the minimum trading unit in Japan.
Compared with the first traded price of 1,301 yen.
You can only enter this lottery through a broker underwriting it. The lead underwriter is SBI Securities, which receives the largest allocation.
Broker pages are in Japanese. A comparison in English is on the brokers page.
A direct-to-consumer company that develops its own supplements and skincare products and sells them mainly through subscriptions on its own online store.
It develops its own products — the supplement Terminalia First, sold under Japan's foods-with-function-claims system, and the Vitabrid C skincare range built on its own patented technology — and sells them directly to consumers through its own online store. Subscriptions are the core of its revenue, and in the year to February 2025 its own site accounted for 91.3% of its total sales. It also wholesales to drugstores and sells through the large online marketplaces. Its parent is Vector, a PR company listed on the Tokyo Stock Exchange Prime market, which held 95.4% of the voting rights at the time of the listing application.
Driven by Terminalia First, revenue in the year to February 2026 rose 21.2% to about 15.3 billion yen and operating profit rose 45.8% to about 1.02 billion yen. For the year to February 2027 the company forecasts revenue of 17.6 billion yen and operating profit of 1.1 billion yen, and it plans to widen its line-up with the GABA range and new products.
Read about this company in Japanese →Figures are taken from the offering documents and public sources, and are checked against two independent sources before publication. Nothing here is investment advice. Shares can and do open below their offer price.
